Business
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and
About this update from Tango Therapeutics, Inc.
[{"type":"text","content":"BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois. “The data we are presenting at this year’s AACR meeting highlights important preclinical analyses of our PRMT5 programs that underscore the potential of these molecules as both standalone treatments and as key combination partners in MTAP-deleted cancers, including in combination with KRAS-inhibitors, paving the way for future development opportunities,” said Adam Crystal, MD, PhD, President of Research and Development. Abstracts accepted for poster presentation Title: Preclinical evaluation of CNS drug penetration of a novel series of MTAP-selective PRMT5 inhibitors including TNG456Abstract #: 463Session Title: Epigenetic TargetsPresenter: Alice Tsai, Ph.D., Executive Director, Tango Therapeutics Date, Time: Sunday April 27, 2025, 2:00pm – 5:00pm CDT Title: TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of solid tumors with MTAP lossAbstract #: 462Session Title: Epigenetic TargetsPresenter: Kimberly Briggs, Ph.D., Director, Tango TherapeuticsDate, Time: Sunday April 27, 2025, 2:00pm – 5:00pm CDT Title: TNG462, an MTA-cooperative PRMT5 inhibitor, demonstrates strong efficacy in combination with clinically relevant targeted therapies in MTAP-null preclinical modelsAbstract #: 2996Session Title: Identification of Molecular Targets 1Presenter: Minjie Zhang, Ph.D., Senior Director, Tango TherapeuticsDate, Time: Monday April 28, 2025, 2:00pm – 5:00pm CDT Title: Evaluation of the impact of homozygous MTAP truncations on the clinical activity of MTA-cooperative PRMT5 inhibitorsAbstract #: 4608Session Title: Molecular Diagnosis, Molecular Characterization and Theranostics of TumorsPresenter: Kimberly Briggs, Ph.D., Director, Tango TherapeuticsDate, Time: Tuesday April 29, 2025, 9:00am – 12:00pm CDT Title: Genetic and pharmacological disruption of the HBS1L/PELO complex impairs mRNA homeostasis and leads to in vivo tumor regressions in FOCAD-deleted cancersAbstract #: 4252Se...